2024-09-21 CD (Suzhou) Biopharma Co., Ltd. HaiPress
SUZHOU,China,Sept. 20,2024 --CD (Suzhou) Biopharma has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application of CD-001,entering a Phase I first-in-human trial.
CD-001,the company's leading clinical candidate,is built on its proprietary Bispecific Fusion Protein (BsFP) platform. This potential therapy,designed to target PD-1 positive CD8+ T cells using an anti-PD-1 antibody and engineered IL-21 mutant,aims to address unmet medical needs in oncology and viral infections.
"The FDA's clearance of this IND reinforces our unwavering commitment to advancing groundbreaking immunotherapies." said Dr. Jian Xu,CEO of CD Biopharma. "CD-001 shows promise as a first-in-class and best-in-class treatment,and preclinical studies have demonstrated its effectiveness in various mouse tumor models,with excellent tolerance observed in non-human primates. We are excited to move forward with patient enrollment and expect initial clinical data in the upcoming months."
About CD (Suzhou) Biopharma
Founded in 2021,CD Biopharma is a rapidly advancing clinical-stage biotech company focused on developing innovative therapies across a broad spectrum of immunotherapy areas,including oncology,viral infections,and autoimmune diseases. The company's proprietary Bispecific Fusion Protein (BsFP) platform and IMmune-Enhanced (IME) cell technology,which enable advanced cell modification,continue to drive breakthrough research and clinical outcomes that transform patient care. CD Biopharma is headquartered in Suzhou,with additional research operations in Beijing,China.
For more information,visit https://www.cdbiopharma.com/.
CONTACT:
E-mail: cd@cdbiopharma.com
CGTN: Xi Jinping's inspection in Guizhou accentuates China's commitment to high-quality development
Synology and Toshiba Strengthen Strategic Partnership with MOU
Fibocom Unveils the First LTE Cat.1 bis Module L610-IN with IRNSS and NAVIC for India
Sino Jet Secures Top Spot in Asia-Pacific Business Jet Fleet for the Sixth Consecutive Year, Five Strategic Pillars Set Industry Benchmark
2024 China-ASEAN College Students' AI Application Innovation Invitation Competition Came to a Successful Concluded
Lemonilo Expansion to Qatar, Bringing Healthier Instant Noodles to the Market
©copyright 2009-2020 Diet Tips Daily